Optics.org
daily coverage of the optics & photonics industry and the markets that it serves
News
Menu
Business News

Profits up at Lumibird despite lidar slip

22 Sep 2021

Strong performance in photonics and medical divisions sees operating income climb.

The Paris-listed laser firm Lumibird has reported a sharp increase in profitability, thanks to a combination of markets recovering from the Covid-19 pandemic and the successful integration of 2020 acquisition Ellex within its medical division.

The company’s stock price rose in value by around 7 per cent after CEO Marc Le Flohic and colleagues revealed a net income of €5.1 million in the first half of 2021.

That compared with a net loss of €1.9 million in the equivalent period of 2020, which included widespread shutdowns as the world reacted to the initial impact of the pandemic.

Partly as a result of the addition of Ellex, total company sales jumped by 65 per cent, to €74.5 million, with earnings before interest, tax, depreciation and amortization (EBITDA) near-doubling to €14.3 million.

Lidar sourcing delays
Lumibird’s photonics division accounted for €34.7 million of that total, up 16 per cent on last year as sales to industrial and scientific markets rose nearly 40 per cent, to €17.1 million.

Sales into defense and space applications also showed a strong increase, with the overall division able to off-set a marked contraction in sales of lidar products and post an EBITDA figure of €6.7 million. Lumibird said that its previously fast-growing lidar business had been hit by sourcing delays.

Acquired for €62 million in mid-2020, the Australia-based laser and ultrasound equipment firm Ellex helped push Lumibird’s medical division sales to €40.7 million - more than double the €15.8 million figure posted for the first half of 2020.

That translated to an EBITDA of €7.6 million for the medical division, up from €2 million a year ago.

Expansion plan
In an investor presentation accompanying the latest results, Lumibird pointed to successful cross-selling, a boom in orders for ultrasound equipment from the US, and a sharp increase in sales of Quantel-branded lasers for glaucoma treatment in Europe as some of the key reasons for the strong performance.

An increase in research and development capacity is also in progress, with a new €7 million, 6000 m2 research and production site just completed.

With around €80 million in cash on the firm’s latest balance sheet, Lumibird’s executive team is confident of expanding the business rapidly - reaffirming the target of doubling sales revenues between 2020 and 2023.

That would imply annual sales approaching €300 million two years from now, a target that should be helped by the pending acquisition of Saab’s laser rangefinder business, and the 37 per cent stake in Orleans-based lasers and optronics firm CILAS that was acquired by Lumibird in July.

• In late trading on the Paris stock market September 22, Lumibird's stock price stood at just over €18 - equivalent to a market captitalization of around €400 million.

AlluxaHÜBNER PhotonicsOcean Insight IncDIAMOND SATRIOPTICS GmbHficonTEC Service GmbHFocuslight Technologies
Copyright © 2022 SPIE EuropeDesigned by Kestrel Web Services